CCC
REGN icon

Crescent Capital Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

Crescent Capital Consulting’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$24K – 524
2021
Q1 		$24K Hold
50
– – 0.01% 340
2020
Q4 		$24K Buy
+50
New +$27K 0.01% 310

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Crescent Capital Consulting's REGN Position: Q2 2021 in Review

Crescent Capital Consulting sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 50 shares — an estimated $24K sold.

Crescent Capital Consulting first reported a position in REGN in Q4 2020 and held it in 2 quarters. The position peaked at $24K in Q1 2021. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

  • Crescent Capital Consulting reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Crescent Capital Consulting sold 50 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $24K.
  • Crescent Capital Consulting first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Crescent Capital Consulting's Regeneron Pharmaceuticals position peaked at $24K in Q1 2021.
  • 971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Crescent Capital Consulting's 13F filing for Q2 2021, filed 15 Jul 2021.